Springer has signed a co-development partnership with the American Society of Gene & Cell Therapy (ASGCT) for the publication of books to be included in the Springer series Advances in Experimental Medicine and Biology. The agreement is to publish four edited volumes per year in the field of gene and cell therapy.
ASGCT will hold editorial responsibility for the books and Springer will handle production, marketing, sales and distribution. The books will be available as eBooks on Springer’s online platform www.springerlink.com and in print-to-order (PTO) format.
Mary Dean, Executive Director of the American Society of Gene & Cell Therapy, said, “The ASGCT leadership is excited to partner with Springer to further the educational missions of both organizations.”
Andrea Macaluso, Editorial Director Biomedicine at Springer, said, “Springer is delighted to collaborate with the American Society of Gene & Cell Therapy on the launch of a book program that will highlight the research accomplishments of their members and encourage original investigation in gene and cell therapy. We look forward to a long and fruitful partnership.”
ASGCT’s mission is to advance knowledge, awareness and education leading to the discovery and clinical application of genetic and cellular therapies. The society is a catalyst for bringing together scientists, physicians, patient advocates and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.